Market Overview

Canaccord Genuity Comments on Recent Journal Manuscripts Related to Thoratec Corporation's HeartMate II Device

Share:

In a report published Friday, Canaccord Genuity analyst Jason R. Mills reiterated a Buy rating and $45.00 price target on Thoratec Corporation (NASDAQ: THOR).

In the report, Canaccord Genuity noted, “The New England Journal of Medicine (NEJM) and Journal of Heart & Lung Transplantation (JHLT) both published manuscripts online just before the Thanksgiving holiday that highlighted an increase in the frequency of device exchanges related to thrombus occurring with HeartMate II devices from Thoratec (THOR : NASDAQ : $42.12 | BUY).”

Thoratec Corporation closed on Wednesday at $42.12.

Latest Ratings for THOR

DateFirmActionFromTo
Sep 2015UpgradesMarket PerformOutperform
Aug 2015DowngradesOutperformMarket Perform
Aug 2015DowngradesOutperformMarket Perform

View More Analyst Ratings for THOR
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Jason R. MillsAnalyst Color Reiteration Analyst Ratings

 

Related Articles (THOR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SKXMaintains44.0
HYMaintains66.0
MSFTMaintains160.0
SKXUpgrades
WLTWMaintains208.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Bank of America Comments on FDA Approval of Bruker Corporation's MALDI Biotyper CA System

Goldman Sachs Comments on News of Archer-Daniels-Midland Company's Proposed Acquisition of GrainCorp Being Blocked by Australian Government